Global escalation in carbapenem-resistant Enterobacterales and carbapenem-resistant Acinetobacter baumannii infections: Serious threat to human health from the pink corner

被引:3
|
作者
Sannathimmappa, Mohan [1 ,2 ]
机构
[1] Natl Univ Sci & Technol, Dept Microbiol Coll Med & Hlth Sci, Sohar, Oman
[2] Natl Univ Sci & Technol, Dept Microbiol Coll Med & Hlth Sci, POB 391,Al Tareef, Sohar 321, Oman
来源
关键词
Acinetobacter; antimicrobial stewardship; carbapenemases; Enterobacterales; healthcare-associated infections; plasmids; CULTURE IDENTIFICATION PANEL; KLEBSIELLA-PNEUMONIAE; RAPID DETECTION; MOLECULAR EPIDEMIOLOGY; EMERGING CARBAPENEMASES; FILMARRAY BLOOD; BETA-LACTAMASE; OXA-48; DETERMINANTS; BACTEREMIA;
D O I
10.4103/bbrj.bbrj_366_22
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Rise in carbapenem-resistant Gram-negative bacterial infections, especially among immunocompromised patients in healthcare settings is an imminent threat as they are difficult to treat and result in a prolonged length of hospital stay, frequent treatment failures, increased economic burden on the patient and the nation, and a high rate of morbidity and mortality. Major carbapenemase-producing Gram-negative bacteria are carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE) such as Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., and others. These bacteria that contaminate health-care settings are the major causes of a wide range of hospital-associated infections including life-threatening septicemia, pneumonia, meningitis, bones and joint infections, and skin and soft-tissue infections. Carbapenems are regarded as last resort available antibiotics to treat multidrug-resistant Gram-negative bacterial infections that show resistance to most of the beta-lactam antibiotics in addition to fluoroquinolones, aminoglycosides, and trimethoprim-sulfamethoxazole. Emergence and spread of carbapenem-resistant Gram-negative pathogens such as CRE and CRAB is a matter of serious concern because of limited treatment options and grave consequences. The World Health Organization has given level one priority to these pathogens and the United States Centers of Disease Control and Prevention considers CRE and CRAB as one of the top five most priority pathogens of public health importance. Strict control measures by the government and public is critical to prevent emergence and dissemination of these dangerous pathogens. In this article, the authors have summarized the microbiological and epidemiological perspectives of CRE and CRAB with a special focus on diagnosis, prevention, and novel promising alternative treatment strategies.
引用
收藏
页码:9 / 16
页数:8
相关论文
共 50 条
  • [41] Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study
    Amanda Vivo
    Margaret A. Fitzpatrick
    Katie J. Suda
    Makoto M. Jones
    Eli N. Perencevich
    Michael A. Rubin
    Swetha Ramanathan
    Geneva M. Wilson
    Martin E. Evans
    Charlesnika T. Evans
    BMC Infectious Diseases, 22
  • [42] Carbapenem-resistant Pseudomonas and Acinetobacter
    Kamarulzaman, A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E38 - E38
  • [43] Carbapenem-Resistant Enterobacterales Infections and Their Association with Rectal Colonization
    Aydemir, Ozlem
    Koroglu, Mehmet
    Ormanoglu, Gokcen
    Ayhanci, Tugba
    Aydemir, Yusuf
    Guclu, Ertugrul
    KONURALP TIP DERGISI, 2023, 15 (03): : 313 - 317
  • [44] Sulbactam and Durlobactam Combination as a Newer Antibiotic for Carbapenem-Resistant Acinetobacter baumannii Infections
    Nyamagoud, Sanatkumar Bharamu
    Swamy, Agadi Hiremath Viswanatha
    Abhishek, B. J.
    Varghese, Leena Elizabeth
    Bhoomika, S. K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2024, 14 (02) : 289 - 298
  • [45] Intravenous Fosfomycin: The Underdog Player in the Treatment of Carbapenem-resistant Acinetobacter baumannii Infections
    Guastalegname, Maurizio
    Trecarichi, Enrico Maria
    Russo, Alessandro
    CLINICAL INFECTIOUS DISEASES, 2023, 77 (12) : 1736 - 1737
  • [46] Clinical characterization of patients with carbapenem-resistant versus carbapenemsusceptible Acinetobacter baumannii infections
    Tyagi, I.
    Koirala, J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E44 - E44
  • [47] Prevalence of carbapenem-resistant Acinetobacter baumannii from 2005 to 2016 in Switzerland
    A. Ramette
    A. Kronenberg
    BMC Infectious Diseases, 18
  • [48] Treatment of patients with serious infections due to carbapenem-resistant Acinetobacter baumannii: How viable are the current options?
    O'Donnell, J. Nicholas
    Putra, Vibert
    Lodise, Thomas P.
    PHARMACOTHERAPY, 2021, 41 (09): : 762 - 780
  • [49] A Novel Triple Combination To Combat Serious Infections with Carbapenem-Resistant Acinetobacter baumannii in a Mouse Pneumonia Model
    Al-Madboly, Lamiaa A.
    MICROBIOLOGY SPECTRUM, 2022, 10 (05):
  • [50] Carbapenem-Resistant Acinetobacter baumannii from Serbia: Revision of CarO Classification
    Novovic, Katarina
    Mihajlovic, Sanja
    Vasiljevic, Zorica
    Filipic, Brankica
    Begovic, Jelena
    Jovcic, Branko
    PLOS ONE, 2015, 10 (03):